Search results for "bleomycin"

showing 10 items of 54 documents

Intravesical bleomycin in bladder tumour prophylaxis.

1986

The authors have evaluated the efficacy, tolerability and systemic absorption of bleomycin administered by intravesical route in the prophylaxis of recurrences of superficial vesical tumours after endoscopic resection (TUR). Thirty mg of bleomycin dissolved in 30 ml of saline solution were instilled in the bladder once a week for the first month and then once a month for 12 months. The instilled fluid was held in the bladder for 1 hour. The systemic absorption of the drug was evaluated by a microbiological assay of bleomycin in plasma and in the perfusion liquid recovered from the bladder. Fifteen patients were treated; most had a long history of multiple recurrent tumours despite previous …

NephrologyMalemedicine.medical_specialtyContact timeUrologymedicine.medical_treatmentBleomycinchemistry.chemical_compoundBleomycinInternal medicinemedicineIntravesical routeHumansSalineAgedCarcinoma Transitional Cellbusiness.industryMiddle AgedSurgeryTolerabilitychemistryUrinary Bladder NeoplasmsNephrologyToxicityFemaleNeoplasm Recurrence LocalbusinessPerfusionInternational urology and nephrology
researchProduct

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, m…

2016

BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to De…

OncologyMaleDenmarkProgrammed Cell Death 1 ReceptorCohort Studies0302 clinical medicineRecurrenceAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineTreatment FailureReed-Sternberg CellsHazard ratioHematologyHodgkin DiseaseVinblastineDacarbazineSTAT1 Transcription FactorItalylymphoma PET Hodgkin030220 oncology & carcinogenesisDisease ProgressionbiomarkerFemalemedicine.drugAdultmedicine.medical_specialtyDacarbazineAntigens Differentiation MyelomonocyticSettore MED/08 - Anatomia PatologicaVinblastineDisease-Free Survival03 medical and health sciencesBleomycinAntigens CDInternal medicineHumansRetrospective StudiesFluorodeoxyglucosebusiness.industryRetrospective cohort studyPET scanmedicine.diseaseLymphomaSurgeryABVDReed–Sternberg cellDoxorubicinPositron-Emission TomographyMultivariate Analysisclassical Hodgkin's lymphoma:PolandbusinessBiomarkers030215 immunology
researchProduct

SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage.

2011

Fibrosis results from inflammatory tissue damage and impaired regeneration. In the context of bleomycin-induced pulmonary fibrosis, we demonstrated that the matricellular protein termed secreted protein acidic and rich in cysteine (SPARC) distinctly regulates inflammation and collagen deposition, depending on its cellular origin. Reciprocal Sparc(-/-) and wild-type (WT) bone marrow chimeras revealed that SPARC expression in host fibroblasts is required and sufficient to induce collagen fibrosis in a proper inflammatory environment. Accordingly, Sparc(-/-) >WT chimeras showed exacerbated inflammation and fibrosis due to the inability of Sparc(-/-) macrophages to down-regulate tumor necrosis …

Pathologymedicine.medical_specialtyAnimals; Bleomycin; Bone Marrow Cells; Chimera; Collagen; Down-Regulation; Fibroblasts; Leukocytes; Macrophages; Mice; Mice Inbred BALB C; Osteonectin; Pneumonia; Pulmonary Fibrosis; Transforming Growth Factor beta; Tumor Necrosis Factor-alphaPulmonary FibrosisDown-RegulationInflammationBone Marrow CellsBiologyPathology and Forensic MedicineMiceFibrosisTumor necrosis factor productionTransforming Growth Factor betaPulmonary fibrosismedicineLeukocytesAnimalsOsteonectinInbred BALB CChimeraTumor Necrosis Factor-alphaMacrophagesMatricellular proteinRegular ArticleSPARCTransforming growth factor betaPneumoniaFibroblastsBLEOMYCINmedicine.diseaseSPARC; BLEOMYCIN; LUNG DAMAGELUNG DAMAGECancer researchbiology.proteinTumor necrosis factor alphaCollagenmedicine.symptomOsteonectin
researchProduct

In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats

2003

1. This study examines the activity of the antioxidant N-acetylcysteine on bleomycin-induced pulmonary fibrosis in rats with emphasis on the early inflammatory phase. 2. Rats receiving N-acetylcysteine (300 mg kg(-1) day(-1), intraperitoneal) had less augmented lung wet weight, and lower levels of proteins, lactate dehydrogenase, neutrophil and macrophage counts in bronchoalveolar lavage fluid and lung myeloperoxidase activity with a betterment of histological score at 3 days postbleomycin. 3. A diminished lung GSH/GSSG ratio and augmented lipid hydroperoxides were observed 3 days postbleomycin. These changes were attenuated by N-acetylcysteine. Alveolar macrophages from bleomycin-exposed r…

PharmacologyPathologymedicine.medical_specialtyNecrosisLungmedicine.diagnostic_testbusiness.industrySuperoxiderespiratory systemmedicine.diseaseBleomycinrespiratory tract diseasesNitric oxideDrug vehiclechemistry.chemical_compoundBronchoalveolar lavageEndocrinologymedicine.anatomical_structurechemistryInternal medicinePulmonary fibrosismedicinemedicine.symptombusinessBritish Journal of Pharmacology
researchProduct

Deglycosylated bleomycin induces apoptosis in lymphoma cell via c-jun NH2-terminal kinase but not reactive oxygen species

2007

Bleomycin (BLM) has demonstrated potent activity in treating malignant lymphomas but its therapeutic efficacy is hampered by induction of lung fibrosis. This side effect is related to the ability of the drug to generate reactive oxygen species in lung cells. In the present study, we evaluated the consequences of deglycosylation of BLM in term of cytotoxic activity and generation of reactive oxygen species. When tested on U937 human lymphoma cells, both compounds generated a typical apoptotic phenotype. Cell death induction was associated with Bax oligomerization, dissipation of the mitochondrial membrane potential, release of cytochrome c, caspase activation, chromatin condensation and inte…

Programmed cell deathFas Ligand ProteinLymphomaCellApoptosisDNA FragmentationBiologymedicine.disease_causeBiochemistryTNF-Related Apoptosis-Inducing LigandBleomycinmedicineHumansDeath domainPharmacologychemistry.chemical_classificationReactive oxygen speciesAntibiotics AntineoplasticU937 cellCytochrome cJNK Mitogen-Activated Protein KinasesU937 CellsMolecular biologymedicine.anatomical_structurechemistryBiochemistryApoptosisCaspasesbiology.proteinReactive Oxygen SpeciesOxidative stressBiochemical Pharmacology
researchProduct

Telomerase and Telomere Length in Pulmonary Fibrosis

2013

In addition to its expression in stem cells and many cancers, telomerase activity is transiently induced in murine bleomycin (BLM)-induced pulmonary fibrosis with increased levels of telomerase transcriptase (TERT) expression, which is essential for fibrosis. To extend these observations to human chronic fibrotic lung disease, we investigated the expression of telomerase activity in lung fibroblasts from patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF). The results showed that telomerase activity was induced in more than 66% of IPF lung fibroblast samples, in comparison with less than 29% from control samples, some of which were obtained from lu…

Pulmonary and Respiratory MedicineMaleTelomerasePathologymedicine.medical_specialtyClinical BiochemistryBiologyBleomycinGene Expression Regulation EnzymologicHistonesTelomerase RNA componentIdiopathic pulmonary fibrosischemistry.chemical_compoundBleomycinMiceFibrosisPulmonary fibrosismedicineAnimalsHumansEmfisema pulmonarPromoter Regions GeneticMolecular BiologyLungTelomeraseCells CulturedMice KnockoutLungAntibiotics AntineoplasticAcetylationCell BiologyArticlesFibroblastsTelomererespiratory systemmedicine.diseaseIdiopathic Pulmonary FibrosisTelomereUp-Regulationrespiratory tract diseasesmedicine.anatomical_structurechemistryPulmonsChronic DiseaseCancer researchFemaleAlveolitis Extrinsic AllergicPulmons Malalties
researchProduct

Electrochemotherapy for advanced cutaneous angiosarcoma: A European register-based cohort study from the International Network for Sharing Practices …

2019

Abstract Background Cutaneous angiosarcoma (cAS) is a highly aggressive malignancy that challenges the radicality of surgical treatment. Electrochemotherapy (ECT), a skin-directed treatment based on cytotoxic chemotherapy combined with local electric pulses, may be an intraoperative adjunct and a new opportunity in the therapeutic strategy. This cohort study reports the experience with ECT as an option. Methods Data on patients with locally-advanced/metastatic cAS who underwent ECT between October 2013 and October 2018 at eight European centres were prospectively submitted to the InspECT (International network for sharing practices of ECT) register. Patients received therapy according to th…

Register basedmedicine.medical_specialtyElectrochemotherapySkin NeoplasmsElectrochemotherapyHemangiosarcomaSkin metastasesTumour controlPainKaplan-Meier EstimateMalignancyCutaneous angiosarcomaCohort Studies03 medical and health sciencesBleomycin0302 clinical medicineAntibioticsSkin Ulcermedicine80 and overHumansAngiosarcomaCutaneous angiosarcoma; Electrochemotherapy; Skin metastases; Skin-directed therapies; Tumour control; Aged; Aged 80 and over; Antibiotics Antineoplastic; Bleomycin; Cohort Studies; Electrochemotherapy; Feasibility Studies; Female; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Middle Aged; Pain; Patient Reported Outcome Measures; Prospective Studies; Registries; Skin Neoplasms; Skin Ulcer; Treatment OutcomePatient Reported Outcome MeasuresProspective StudiesRegistriesSkin-directed therapiesAgedAged 80 and overInternational networkAntibiotics Antineoplasticbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseAntineoplasticmedicine.anatomical_structureTreatment OutcomeTolerability030220 oncology & carcinogenesisScalpFeasibility Studies030211 gastroenterology & hepatologySurgeryFemaleRadiologybusinessCohort studyInternational journal of surgery (London, England)
researchProduct

Immune ambivalence: The schizophrenic bleomycin.

2013

In addition to cytotoxic effects, anticancer agents can exert multiple immunomodulatory functions. We have recently described the molecular mechanisms whereby bleomycin can 1) promote endoplasmic reticulum stress, causing the immunogenic death of cancer cells and hence strengthening antitumor CD8+ T cell responses; and 2) induce the secretion of transforming growth factor β (TGFβ), which stimulates regulatory T cells. This suggests that bleomycin may be favorably combined with TGFβ-targeting strategies.

T cellImmunologyBleomycinregulatory T cellschemistry.chemical_compoundImmune systemimmunogenic cell deathmedicineImmunology and AllergyCytotoxic T cellAuthor's Viewtransforming growth factor betabiologybusiness.industryTransforming growth factor betamedicine.anatomical_structuremouse studyOncologychemistryCancer cellImmunologyCancer researchbiology.proteinImmunogenic cell deathbusinessbleomycineTransforming growth factorOncoimmunology
researchProduct

Species-specific aggregation factor in sponges V. Influence on programmed syntheses

1976

Isolated cells from the siliceous sponge Geodia cydonium as well as small primary aggregates (diameter: 70 mum) consisting of them show no increase in rates of programmed syntheses and mitotic activity with time. After addition of a highly purified aggregation factor to a culture with primary aggregates which subsequently form secondary aggregates (diameter: larger than 1000 mum), a dramatic increase of DNA, RNA and protein synthesis occurs. Together with this increase, the cells show a high mitotic activity. The values for the mitotic coefficient reach a first maximum 8 h after the beginning of the secondary aggregation process. The stimulation of the mitotic activity of cells during the a…

Time FactorsCellPopulationStimulationBiologyModels BiologicalBiochemistry Genetics and Molecular Biology (miscellaneous)Bleomycinchemistry.chemical_compoundSpecies SpecificitymedicineProtein biosynthesisAnimalseducationMitosisCell Aggregationeducation.field_of_studyDNA synthesisRNADNAPoriferamedicine.anatomical_structurechemistryBiochemistryProtein BiosynthesisDactinomycinBiophysicsRNAPuromycinColchicineCell DivisionDNABiochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis
researchProduct

Deglycosylated bleomycin triggers apoptosis in laryngeal carcinoma cells in a caspase and reactive oxygen species independent manner

2008

Background:  Bleomycin-A2, a member of a family of glycopeptide antibiotics, has potent antitumor activity against a range of lymphomas, head and neck cancer and germ cell tumors. However, little is known about the biologic activity of the carbohydrate moiety in Bleomycin-A2-induced cytotoxicity. Methods:  We compared the capacity of Bleomycin-A2 and its deglycosylated form (deglycoBleomycin-A2) to induce cell death. Apoptosis was analyzed by cell nuclear staining with Hoechst 33342 dye and DNA fragmentation. The signal transduction pathway was measured through Western blotting and production of reactive oxygen species (ROS). Results:  When tested on HEp-2 laryngeal carcinoma cells, Bleomyc…

chemistry.chemical_classificationCancer ResearchReactive oxygen speciesProgrammed cell deathbiologyMolecular biologyPathology and Forensic MedicineOtorhinolaryngologyBleomycin A2chemistryApoptosisImmunologybiology.proteinPeriodonticsDNA fragmentationViability assayOral SurgeryCytotoxicityCaspaseJournal of Oral Pathology & Medicine
researchProduct